Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Pharma
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
With the FDA’s approval of Winrevair to treat pulmonary arterial hypertension, Merck is set to launch the first disease-modifying treatment for PAH.
Kevin Dunleavy
Mar 26, 2024 5:11pm
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
Mar 25, 2024 11:05am
J&J sues ex-staffer for allegedly taking secret docs to Pfizer
Mar 21, 2024 9:08am
Idorsia's Tryvio nabs FDA approval following buyback from J&J
Mar 20, 2024 12:40pm
UPDATED: FDA advisers back Carvykti, Abecma in earlier myeloma
Mar 15, 2024 1:58pm
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
Mar 15, 2024 10:15am